China-based ophthalmology specialist Arctic Vision has announced the enrollment of the first patient in a Phase III clinical study assessing the efficacy and safety of ARVN002 (atropine sulfate) for arresting myopia progression. The study is being conducted in China and marks a significant step forward in the development of this innovative treatment.
ARVN002: Drug Overview
ARVN002 is an innovative micro-dosing formulation of atropine delivered via the Optejet device. The product is designed to treat myopia and has shown therapeutic effects in previous studies, providing the highest level of evidence for its efficacy. Arctic Vision obtained the clinical development and commercialization rights to ARVN002 in Greater China and South Korea through a licensing deal in August 2020.
Optejet Delivery System
The Optejet delivery system enhances the comfort and ease of use for children. Utilizing patented Microdose Array Print (MAP) technology, Optejet can quickly and evenly distribute micro-medicine within 80 milliseconds. Each dose is approximately 8 μL, which is about 80% less than conventional eye drop administration. This reduces the risk of ocular and systemic adverse reactions caused by overdose and ensures more efficient and precise drug delivery. Additionally, the built-in Bluetooth module of the Optejet system can connect to an app for personalized settings, drug delivery monitoring, and improved compliance tracking.
Future Outlook
The Phase III clinical study of ARVN002 represents a crucial milestone in Arctic Vision’s efforts to address myopia progression. The innovative micro-dosing approach and advanced delivery system are expected to provide a more effective and user-friendly treatment option for patients.-Fineline Info & Tech
